Analysts’ Weekly Ratings Changes for Clearside Biomedical (CLSD)

Several brokerages have updated their recommendations and price targets on shares of Clearside Biomedical (NASDAQ: CLSD) in the last few weeks:

• 3/31/2025 – Clearside Biomedical had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
• 3/28/2025 – Clearside Biomedical had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
• 3/28/2025 – Clearside Biomedical had its price target lowered by analysts at Needham & Company LLC from $6.00 to $4.00. They now have a “buy” rating on the stock.
• 3/18/2025 – Clearside Biomedical was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 3/6/2025 – Clearside Biomedical had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
• 3/6/2025 – Clearside Biomedical had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.

Clearside Biomedical Stock Performance

Shares of CLSD stock traded down $0.00 during midday trading on Monday, reaching $0.86. 196,439 shares of the company were exchanged, compared to its average volume of 350,058. The company’s 50 day moving average price is $0.96 and its two-hundred day moving average price is $1.03. The company has a market cap of $66.11 million, a P/E ratio of -1.90 and a beta of 2.03. Clearside Biomedical, Inc. has a 12 month low of $0.77 and a 12 month high of $1.65.

Clearside Biomedical (NASDAQ:CLSD) last announced its earnings results on Thursday, March 27th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.03. The firm had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.27 million. As a group, sell-side analysts predict that Clearside Biomedical, Inc. will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On Clearside Biomedical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in shares of Clearside Biomedical by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 764,058 shares of the company’s stock worth $726,000 after purchasing an additional 32,672 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Clearside Biomedical by 24.0% in the 4th quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock worth $157,000 after acquiring an additional 32,048 shares during the last quarter. Finally, Investor s Fiduciary Advisor Network LLC acquired a new stake in shares of Clearside Biomedical during the fourth quarter worth $32,000. 18.75% of the stock is owned by institutional investors and hedge funds.

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.